Long-term Follow-up After a Switch to Bictegravir,
Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine
IDWeek 2020 Oct 21-25 virtual
Reported by Jules Levin
References: 1. Clinical Info HIV.gov. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV; 7/10/19; 2. EACS Guidelines Version 10.1 October 2020; 3. Saag MS, et al, JAMA 2018;320:379-96; 4. Molina JM, et al. Lancet HIV 2018;5:e357-65. Acknowledgments: This study was funded by Gilead Sciences, Inc.
